Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (25): 5660–5669.

https://doi.org/10.1182/blood-2010-06-290536

Published: 2010

Includes: Supplemental data

Journal Articles

Mutations In the Tet Oncogene Family Member 2 ( TET2 ) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

Blood (2010) 116 (21): 98.

https://doi.org/10.1182/blood.V116.21.98.98

Published: 2010

Journal Articles

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

Heiko Becker, MD, Kati Maharry, MAS, Michael D. Radmacher, PhD, Dean Margeson, MAS, Krzysztof Mrózek, MD, PhD, Susan P. Whitman, PhD, Yue-Zhong Wu, MS, Klaus H. Metzeler, MD, Sebastian Schwind, MD, Kelsi B. Holland, MS, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Michael A. Caligiuri, MD, Maria R. Baer, MD, Richard A. Larson, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2010) 116 (21): 577.

https://doi.org/10.1182/blood.V116.21.577.577

Published: 2010

Journal Articles

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (18): 3622–3626.

https://doi.org/10.1182/blood-2010-05-283648

Published: 2010

Includes: Supplemental data

Journal Articles

Mutations of the Wilms tumor 1 gene ( WT1 ) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (5): 788–792.

https://doi.org/10.1182/blood-2010-01-262543

Published: 2010

Includes: Supplemental data

Journal Articles

Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study.

Sebastian Schwind, MD, Guido Marcucci, MD, Kati Maharry, MAS, Krzysztof Mrózek, MD, PhD, Michael D. Radmacher, PhD, Kelsi B. Holland, MS, Heiko Becker, MD, Susan P. Whitman, PhD, Yue-Zhong Wu, MS, Maria R Baer, MD, Bayard L. Powell, MD, Andrew J. Carroll, PhD, Michael A. Caligiuri, MD, Richard A. Larson, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 214.

https://doi.org/10.1182/blood.V114.22.214.214

Published: 2009

Journal Articles

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

Eyal C. Attar, MD, Kati Maharry, MAS, Krzysztof Mrózek, MD, PhD, Michael D. Radmacher, PhD, Susan P. Whitman, PhD, Peter Paschka, MD, Christian Langer, MD, Kelsi B. Holland, MS, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard A. Larson, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 1616.

https://doi.org/10.1182/blood.V114.22.1616.1616

Published: 2009

Journal Articles

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

Susan P. Whitman, PhD, Kati Maharry, MAS, Michael D. Radmacher, PhD, Krzysztof Mrózek, MD, PhD, Dean Margeson, MAS, Kelsi B. Holland, MS, Heiko Becker, MD, Yue-Zong Wu, MS, Sebastian Schwind, MD, Maria R Baer, MD, Bayard L. Powell, MD, Richard M Stone, MD, Andrew J. Carroll, PhD, Richard A. Larson, MD, Michael A. Caligiuri, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 1579.

https://doi.org/10.1182/blood.V114.22.1579.1579

Published: 2009

Journal Articles

Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study.

Krzysztof Mrózek, MD, PhD, Kelsi B. Holland, MS, Mark J. Pettenati, PhD, Kati Maharry, MAS, Guido Marcucci, MD, Maria R. Baer, MD, Jonathan E. Kolitz, MD, Dean Margeson, MAS, Colin G. Edwards, PhD, Andrew J. Carroll, PhD, Richard A. Larson, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 2602.

https://doi.org/10.1182/blood.V114.22.2602.2602

Published: 2009

NARROW

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Mutations In the Tet Oncogene Family Member 2 ( TET2 ) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Mutations of the Wilms tumor 1 gene ( WT1 ) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only